Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
When patients learn about the unknowns surrounding a cancer drug's benefits and risks, they're significantly less likely to choose it. A pair of randomized clinical trials involving over 6,000 U.S. adults found that disclosing even a single uncertainty dropped patients' willingness to take a drug by about 10 percentage points — and the more uncertainties disclosed, the greater the hesitancy.
When it comes to cancer drugs approved on limited evidence, what patients don't know may be shaping their decisions in ways that aren't fully informed. Two new randomized clinical trials published in JAMA Internal Medicine found that simply informing patients about uncertainties surrounding a cancer drug's benefits and risks meaningfully reduced their likelihood of choosing to take it.
The study enrolled 6,272 U.S. adults and tested how different types of uncertainty disclosures — such as a drug being studied only in a short trial, on an unrepresentative population, or using an unvalidated surrogate endpoint — affected treatment decisions. The effect was consistent: more information about unknowns led to less willingness to proceed with treatment, in what researchers described as a dose-dependent pattern.
Why it matters: Oncology drugs are often approved based on limited or uncertain evidence, yet patients rarely hear about these gaps. Researchers suggest that standardized plain-language uncertainty summaries — starting with the FDA website and potentially extending to drug labels and clinical guidelines — could help patients make truly informed treatment decisions.
